Alligator Bioscience AB (publ) (STO:ATORX)
Sweden · Delayed Price · Currency is SEK 0.0112
+0.0001 (0.90%)
Nov 4, 2026, 9:02 AM CET
Alligator Bioscience AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 0.28 | 0.51 | 57.77 | 58.11 | 35.7 | 12.94 |
Other Revenue | 0.63 | 0.33 | -0.04 | 1.14 | 0.31 | 0.38 |
| 0.92 | 0.84 | 57.72 | 59.25 | 36 | 13.33 | |
Revenue Growth | -97.85% | -98.55% | -2.58% | 64.58% | 170.14% | 141.65% |
Cost of Revenue | 68.31 | 77.5 | 167.21 | 218.79 | 147.73 | 86.98 |
Gross Profit | -67.39 | -76.66 | -109.48 | -159.54 | -111.72 | -73.66 |
Selling, General & Admin | 27.29 | 43.29 | 70.43 | 79.38 | 68.84 | 56.85 |
Other Operating Expenses | -1.18 | -0.25 | -0.12 | -0.02 | -0.03 | -0 |
Operating Expenses | 27.14 | 45 | 80.83 | 89.85 | 80.58 | 68 |
Operating Income | -94.53 | -121.66 | -190.31 | -249.39 | -192.3 | -141.65 |
Interest Expense | -21.38 | -44.27 | -15.33 | -0.48 | -0.65 | -0.23 |
Interest & Investment Income | 0.18 | 0.27 | 1.31 | 1.88 | - | - |
Currency Exchange Gain (Loss) | -0.16 | 0.43 | -1.27 | -0.6 | -0.46 | -0.14 |
Other Non Operating Income (Expenses) | 32.86 | 96.91 | 9.92 | 0 | 0 | - |
EBT Excluding Unusual Items | -83.04 | -68.31 | -195.68 | -248.59 | -193.41 | -142.03 |
Gain (Loss) on Sale of Assets | -1.31 | 2.27 | - | - | - | - |
Asset Writedown | - | 12.2 | -38.21 | - | - | - |
Other Unusual Items | 2.25 | 2.49 | - | - | - | -0.96 |
Pretax Income | -82.1 | -51.35 | -233.89 | -248.59 | -193.4 | -141.74 |
Net Income | -82.1 | -51.35 | -233.89 | -248.59 | -193.4 | -141.74 |
Net Income to Common | -82.1 | -51.35 | -233.89 | -248.59 | -193.4 | -141.74 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 456 | 28 | 1 | 0 | 0 | 0 |
Shares Outstanding (Diluted) | 456 | 28 | 1 | 0 | 0 | 0 |
Shares Change | 2618.56% | 3648.83% | 63.72% | 103.32% | 146.00% | 25.61% |
EPS (Basic) | -0.18 | -1.87 | -318.53 | -554.27 | -876.77 | -1580.64 |
EPS (Diluted) | -0.18 | -1.87 | -318.53 | -554.27 | -880.00 | -1580.64 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -98.76 | -157.45 | -221.78 | -191.74 | -173.05 | -127.08 |
Free Cash Flow Per Share | -0.22 | -5.72 | -302.04 | -427.53 | -784.49 | -1417.17 |
Gross Margin | - | - | -189.67% | -269.26% | - | - |
Operating Margin | -10331.04% | -14500.48% | -329.70% | -420.90% | -534.16% | -1062.89% |
Profit Margin | -8972.90% | -6120.38% | -405.19% | -419.55% | -537.22% | -1063.52% |
Free Cash Flow Margin | -10793.00% | -18765.91% | -384.21% | -323.61% | -480.67% | -953.54% |
EBITDA | -95.21 | -121.41 | -189.37 | -248.24 | -188.89 | -136.7 |
D&A For EBITDA | -0.68 | 0.25 | 0.95 | 1.15 | 3.41 | 4.95 |
EBIT | -94.53 | -121.66 | -190.31 | -249.39 | -192.3 | -141.65 |
Revenue as Reported | 1.44 | 6.42 | 59.71 | 61.9 | 37.14 | 15.13 |